RPS6KB2 and breast carcinoma: Amplification of RPS6KB2 was associated with an overall survival rate of ≤70% among patients with all previously mentioned cancer types, except for breast cancer, where patients with RPS6KB2 amplification had an overall survival rate of 86.5%.